The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and Proliferation

Blood Cancer Journal

Volumn 1, Issue 2, 2011, Pages

  Vandyke, K ^a,b   Fitter, S ^a   Zannettino, A C W ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BONE GROWTH; CARTILAGE CELL; CELL PROLIFERATION; DRUG EFFICACY; HISTOLOGY; LETTER; NONHUMAN; OSTEOBLAST; RAT;

EID: 84864069592     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.1     Document Type: Letter

References (23)

1. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661. (Pubitemid 40053752)
2. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006; 103: 3153-3158. (Pubitemid 43346440)
3. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009; 23: 994-997.
4. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
5. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008; 372: 111-112. (Pubitemid 351958458)
6. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89: 251-252.
7. Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009; 94: 1177-1179.
8. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial [abstract]. Blood 2009; 114: 863.
9. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009; 23: 2155-2159.
10. Kieswetter K, Schwartz Z, Alderete M, Dean DD, Boyan BD. Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation. Endocrine 1997; 6: 257-264. (Pubitemid 27431396)
11. Weiser L, Bhargava M, Attia E, Torzilli PA. Effect of serum and platelet-derived growth factor on chondrocytes grown in collagen gels. Tissue Eng 1999; 5: 533-544.
12. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954-963.
13. Gemba T, Valbracht J, Alsalameh S, Lotz M. Focal adhesion kinase and mitogen-activated protein kinases are involved in chondrocyte activation by the 29-kDa amino-terminal fibronectin fragment. J Biol Chem 2002; 277: 907-911. (Pubitemid 34968833)
14. Gill KS, Beier F, Goldberg HA. Rho-ROCK signaling differentially regulates chondrocyte spreading on fibronectin and bone sialoprotein. Am J Physiol Cell Physiol 2008; 295: C38-C49. (Pubitemid 352755815)
15. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702. (Pubitemid 121001157)
16. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010; 25: 1759-1770.
17. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29: 3196-3207.
18. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010; 10: 298.
19. Gill KS, Beier F, Goldberg HA. Rho-ROCK signaling differentially regulates chondrocyte spreading on fibronectin and bone sialoprotein. Am J Physiol Cell Physiol 2008; 295: C38-C49. (Pubitemid 352755815)
20. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702. (Pubitemid 121001157)
21. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010; 25: 1759-1770.
22. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29: 3196-3207.
23. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010; 10: 298.